20
total announcements
524715.BO · 15 min delayed
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd has announced the schedule of upcoming analyst/institutional investor meetings, including UBS India Summit 2026, Jefferies India Forum 2026, and J.P. Morgan India Conference 2026, without disclosing any unpublished price sensitive information.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd participated in a White House ceremony to announce agreements with the U.S. government to prioritize access to affordable medicines for millions of American patients.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd has published newspaper advertisements containing information about Postal Ballot/E-Voting.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd has announced a notice of postal ballot/e-voting for the reclassification of certain individuals from the 'Promoter Group' to the 'Public' category, which will reduce the promoter group holding from 54.48% to 52.68% and increase public holding from 45.52% to 47.32%. The reclassification is subject to requisite approvals and will not affect control, management, or business operations.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd has announced the schedule of upcoming analyst/institutional investor meetings, to be held on 01-Sept-26 at Ashwamedh – Elara India Dialogue 2026 in Mumbai. The company will not disclose any unpublished price sensitive information at these meetings.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd has been a defendant in antitrust litigation in the US related to a 2008 patent litigation settlement agreement with Pfizer concerning generic Lipitor. The US Court of Appeals has affirmed the order in favour of the Company, bringing the litigation substantially to a close.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd has received no-objection letters from the National Stock Exchange of India Limited and BSE Limited for the reclassification of certain promoters from the 'Promoter Group' category to the 'Public' category.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd has announced its Q1 FY27 earnings, with sales growing 10.1% to INR1,51,836 million, gross margin at 80.5%, and EBITDA margins at 28.9%. The company also mentioned a charge of INR1,617 million towards Organon's acquisition-related costs.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd has announced the schedule of upcoming analyst/institutional investor meetings, as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meetings will be held on August 10, 12, and 13, 2026, at various locations in Mumbai. The company will not disclose any unpublished price sensitive information (UPSI) at these meetings.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd has received a reaffirmation of its long-term bank facilities credit rating by CRISIL, with the rating being removed from 'Rating Watch with Developing Implications' and reaffirmed at 'CRISIL AAA/Stable'.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd has published newspaper advertisements containing information about the unaudited financial results for the quarter ended 30 June 2026. Copies of the newspaper clippings are attached as Annexure-A and are also available on the company's website.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd has announced the voting results and scrutinizer report for its 34th Annual General Meeting (AGM) held on July 31, 2026, where all resolutions were passed with the requisite majority.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd held its 34th Annual General Meeting on 31 July 2026, approving various resolutions including the adoption of audited financial statements, appointment of directors, and declaration of final dividend. The meeting was conducted through video conferencing, and remote e-voting was made available to shareholders. The company's chairman delivered a speech highlighting its performance, with consolidated revenues growing 11.9% to ₹582 billion and EBITDA increasing 16.1% to ₹177 billion.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd has made the audio recording of its Q1FY27 investor call available on its website, as per Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd has concluded its Board Meeting held on 31 July 2026, which commenced at 10:50 A.M. and concluded at 3:40 P.M.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd has announced its unaudited standalone and consolidated financial results for Q1 of FY 2026-27, with revenue from operations at ₹57,411.3 crore and other income at ₹1,401.7 crore.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd has received approval from the Brazilian Health Regulatory Agency, ANVISA, to manufacture and market semaglutide injection in Brazil for the treatment of inadequately controlled type 2 diabetes mellitus.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd has announced the opening of a special window for the transfer of physical shares that were sold or purchased prior to April 1, 2019, including transfer requests that were previously rejected or returned due to deficiencies in documents or process.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd's partner Philogen has resubmitted the marketing authorization application for Nidlegy, a biopharmaceutical product for the treatment of skin cancers, to the European Medicines Agency (EMA).
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd has announced that Organon shareholders have approved the proposed acquisition of Organon by Sun Pharma, a significant milestone towards the completion of the transaction.